July 21 (Reuters) - Nuvalent Inc NUVL.O:
NUVALENT ANNOUNCES INITIATION OF ALKAZAR PHASE 3 RANDOMIZED, CONTROLLED TRIAL EVALUATING NELADALKIB FOR PATIENTS WITH TKI-NAÏVE ALK-POSITIVE NSCLC
NUVALENT INC - ALKAZAR TRIAL TO ENROLL 450 TKI-NAÏVE ALK-POSITIVE NSCLC PATIENTS
Source text: ID:nPn9TTbDRa
Further company coverage: NUVL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.